A recent systematic review and meta-analysis designed to clarify the use of MR-proADM in severe COVID-19 disease included 21 studies, published between 2020 and 2022 from European countries, addressing the use of pro-adrenomedullin in COVID-19 (9). This evidence concerns the gene ADM and COVID-19.